KIT and neoplasm: The role of c-KIT in tumors is highlighted by the reports that treatment with its inhibitors, the Imatinib Mesylate (Glivec) and Sunitinib (Sutent) (targeted cancer therapy), result in the inhibition of the tumor cells of some cancers [33,34,35,36,37,38,39].